How should hyperuricemia be prevented and treated in a patient undergoing cytotoxic chemotherapy, including hydration, allopurinol, rasburicase, febuxostat, monitoring, and considerations for G6PD deficiency and renal impairment?

Hyperuricemia Management in Cytotoxic Chemotherapy

For patients undergoing cytotoxic chemotherapy, risk-stratify first, then use rasburicase for high-risk patients, hydration plus allopurinol or rasburicase for intermediate-risk patients, and close monitoring alone for low-risk patients. 1

Risk Stratification Framework

Before initiating any prophylaxis, classify patients by TLS risk using tumor type and disease burden 1:

High-Risk Patients:

• Burkitt's lymphoma, lymphoblastic lymphoma, or B-ALL
• ALL with WBC ≥100,000
• AML with WBC ≥50,000 or monoblastic subtype
• Any malignancy with rapid proliferation and expected rapid response

Intermediate-Risk Patients:

• Diffuse large B-cell lymphoma
• ALL with WBC 50,000-100,000
• AML with WBC 10,000-50,000
• CLL with WBC 10,000-100,000 treated with fludarabine

Low-Risk Patients:

• Indolent NHL
• ALL with WBC <50,000
• AML with WBC <10,000
• CLL with WBC <10,000

Prevention Strategy by Risk Level

High-Risk Patients

Use prophylactic rasburicase 1. Rasburicase provides superior uric acid reduction compared to allopurinol (uric acid AUC 128 vs 328 mg·hr/dL) 2. The drug works within 4 hours, reducing uric acid by a median of 9.1 mg/dL in patients with baseline levels ≥8 mg/dL 2.

• Dose: 0.15-0.2 mg/kg IV over 30 minutes once daily 2
• Timing: Start 4-48 hours before chemotherapy 2
• Duration: Continue 5-7 days after chemotherapy initiation 2
• Hydration: Maintain urine output ≥2 liters/day 3

Intermediate-Risk Patients

Use hydration plus either allopurinol OR rasburicase 1. The choice depends on baseline uric acid and renal function:

Allopurinol approach:

• Start 100 mg daily, increase weekly by 100 mg increments until uric acid ≤6 mg/dL (maximum 800 mg/day) 3
• Begin several days before chemotherapy since allopurinol only prevents new uric acid formation and takes days to work 1
• Add colchicine prophylaxis to prevent gout flares during initial treatment 3
• Critical limitation: Cannot reduce pre-existing elevated uric acid 1

Rasburicase approach (preferred if baseline uric acid elevated):

• Same dosing as high-risk patients
• More rapid onset than allopurinol 4

Low-Risk Patients

Close monitoring only 1. No prophylactic medication required, but maintain adequate hydration.

Critical Contraindication: G6PD Deficiency

Screen for G6PD deficiency before administering rasburicase 2, 5. Rasburicase produces hydrogen peroxide during uric acid metabolism, which causes severe hemolytic anemia in G6PD-deficient patients 5. This is an absolute contraindication 2.

If G6PD deficiency is present or suspected:

• Use allopurinol instead 5
• Consider febuxostat as alternative 5
• Never use rasburicase

Renal Impairment Considerations

For Allopurinol:

Reduce initial dose in renal impairment 3. Patients with decreased renal function require lower starting doses than the standard 100 mg daily 3. The half-life of oxipurinol (active metabolite) is greatly prolonged in severe renal impairment 3.

• Severe renal impairment: Consider 100 mg every other day or 300 mg twice weekly 3
• Monitor closely during early treatment stages 3

For Febuxostat:

No dose adjustment needed for mild-to-moderate renal impairment 6, 7. This represents a significant advantage over allopurinol 6, 8.

• Effective in stage 4-5 CKD (reduces uric acid by 1.85 mg/dL without worsening eGFR) 7
• Standard dosing: Start 40 mg daily, increase to 80 mg after 2 weeks if uric acid remains >6 mg/dL 6
• Caution: Limited data in severe renal impairment 6

For Rasburicase:

No dose adjustment required 2. Rasburicase is not renally cleared and maintains efficacy regardless of renal function.

Essential Monitoring

Monitor the following parameters:

• Uric acid levels: Baseline, 4 hours after first dose, then every 4-6 hours initially
• Electrolytes (potassium, phosphorus, calcium): Every 4-6 hours for first 24-48 hours
• Renal function (BUN, creatinine): Daily
• Urine output: Maintain ≥2 liters/day 3

Critical Pitfalls to Avoid

1. Do NOT alkalinize urine 1. This outdated practice is no longer recommended and may promote calcium phosphate precipitation.

2. Allopurinol drug interactions: Reduce 6-mercaptopurine and azathioprine doses by 75% when co-administered 1. Allopurinol is contraindicated with cyclophosphamide due to increased bone marrow suppression 1.

3. Rasburicase specimen handling: Blood samples for uric acid must be placed immediately on ice and analyzed within 4 hours to prevent ex vivo uric acid degradation 2.

4. Xanthine precipitation: Allopurinol blocks xanthine oxidase, causing xanthine accumulation that can precipitate in renal tubules 1. This risk is eliminated with rasburicase 4.

5. Delayed chemotherapy with allopurinol: If baseline uric acid is elevated, allopurinol may require delaying chemotherapy for several days to achieve adequate uric acid reduction 1. Rasburicase avoids this delay 4.